Bristol-Myers executive charged with insider trading

Thu Aug 2, 2012 1:08pm EDT

Related Topics

(Reuters) - A Bristol-Myers Squibb Co executive has been criminally charged with insider trading, accused of buying options in three companies that the drugmaker was looking to buy.

Prosecutors said Robert Ramnarine, 45, made about $311,361 in illegal profit between August 2010 and July 2012 by buying call options in ZymoGenetics Inc and Pharmasset Inc and call and put options in Amylin Pharmaceuticals Inc, shortly before those pharmaceutical companies agreed to takeovers.

Ramnarine, who was promoted in July to assistant treasurer for capital markets, was charged with three counts of securities fraud, according to a complaint made public on Thursday in the federal court in Newark, New Jersey. Each count carries a maximum penalty of 20 years in prison and a $5 million fine.

The U.S. Securities and Exchange Commission filed separate civil fraud charges against Ramnarine, and seeks both to recover illegal profit and to freeze the East Brunswick, New Jersey, resident's brokerage account assets.

Ken Dominski, a Bristol-Myers spokesman, said the New York-based company is cooperating with the government and has put Ramnarine on administrative leave. "Bristol-Myers Squibb has clear and strict policies prohibiting trading on material non-public information," he said.

Ramnarine was arrested Thursday morning and is expected to appear in federal court later in the day, said a spokesman for U.S. Attorney Paul Fishman in New Jersey. It is unclear whether Ramnarine has hired a lawyer for his defense.

According to the complaint, Ramnarine learned confidential information about potential takeovers while working as a director or executive director in Bristol-Myers' pension and savings investments office in Princeton, New Jersey.

The complaint said that before buying the Pharmasset options, Ramnarine conducted several Internet searches on Yahoo from his office concerning detection of insider trading.

These searches included "can option be traced to purchaser" and "insider trading options traceillegal (sic)," and included a review of an August 2005 SEC press release over alleged insider trading in Reebok International Ltd call options.

Bristol-Myers bought ZymoGenetics for $885 million in October 2010. It expects to complete its $5.3 billion purchase of Amylin this month.

Gilead Sciences Inc agreed in November to buy Pharmasset after Bristol-Myers dropped out of talks. Gilead completed the $11 billion acquisition in January.

The case is U.S. v. Ramnarine, U.S. District Court, District of New Jersey, No. 12-md-08121.

(Reporting By Jonathan Stempel and Ransdell Pierson in New York; Editing by Lisa Von Ahn, John Wallace and Bernard Orr)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
deb1ryan wrote:
This guy is a scapegoat, but he should get prosecuted. But, look at Lucent Technologies. Pat Russo and her board of dirctors lied to the SEC about the value of the company for a long time, stock split and split. When they finally turned in the real number, they caused the stock to go from $110 per share to about $1.50. Took down all kinds of pension plans. All the while they were lying, they were selling hundreds of thousand of shares of stock and making Millions. Of course they were giving money to George Bush for his thievery of the presidential office, so no one got prosecuted. What’s one more White Collar criminal that doesn’t get proscueted, but send that guy smoking a joint to prison!!!!!

Aug 06, 2012 9:08am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.